NURIX THERAPEUTICS INC's ticker is NRIX and the CUSIP is 67080M103. A total of 122 filers reported holding NURIX THERAPEUTICS INC in Q1 2023. The put-call ratio across all filers is 0.01 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $64,000 | +10.3% | 8,107 | +39.7% | 0.00% | – |
| Q2 2023 | $58,000 | +141.7% | 5,804 | +112.9% | 0.00% | – |
| Q1 2023 | $24,000 | -68.8% | 2,726 | -61.5% | 0.00% | – |
| Q4 2022 | $77,000 | +670.0% | 7,083 | +816.3% | 0.00% | – |
| Q3 2022 | $10,000 | +150.0% | 773 | +119.0% | 0.00% | – |
| Q2 2022 | $4,000 | -85.7% | 353 | -82.6% | 0.00% | – |
| Q1 2022 | $28,000 | -86.3% | 2,027 | -71.4% | 0.00% | – |
| Q4 2021 | $205,000 | +2177.8% | 7,095 | +2196.1% | 0.00% | – |
| Q3 2021 | $9,000 | +125.0% | 309 | +111.6% | 0.00% | – |
| Q2 2021 | $4,000 | -94.1% | 146 | -93.3% | 0.00% | – |
| Q1 2021 | $68,000 | +423.1% | 2,190 | +440.7% | 0.00% | – |
| Q4 2020 | $13,000 | +333.3% | 405 | +305.0% | 0.00% | – |
| Q3 2020 | $3,000 | – | 100 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Bain Capital Life Sciences Investors, LLC | 1,822,883 | $14,327,860 | 1.60% |
| DAFNA Capital Management LLC | 556,695 | $4,375,623 | 1.36% |
| Redmile Group, LLC | 2,848,827 | $22,391,780 | 1.06% |
| Deep Track Capital, LP | 2,997,830 | $23,562,944 | 0.91% |
| WestHill Financial Advisors, Inc. | 283,333 | $2,226,997 | 0.65% |
| Soleus Capital Management, L.P. | 814,000 | $6,398,040 | 0.59% |
| Affinity Asset Advisors, LLC | 250,000 | $1,965,000 | 0.55% |
| Boxer Capital, LLC | 1,224,892 | $9,627,651 | 0.51% |
| AtonRa Partners | 24,227 | $190,424 | 0.40% |
| WASATCH ADVISORS LP | 3,564,616 | $28,017,882 | 0.18% |